Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-BCT-100 in relapsed or refractory AML
NCT02899286Phase 2Unknown
- Sponsor
- Bio-Cancer Treatment International Limited
- Start
- Sep 2016
- Primary completion
- Sep 2019
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of arginase in acute myeloid leukemia (AML), sponsored by Bio-Cancer Treatment International Limited. Status: unknown.
02
Drugs
arginase
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02899286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02899286.